Harnessing a proprietary bioinformatics platform, MiNA is rapidly discovering and developing saRNAs to selectively upregulate protein expression.
saRNAs recruit endogenous transcriptional complexes to a target gene, leading to increased expression of naturally processed mRNA that replicate full target gene functionality.
Gene activation by saRNAs is accompanied by promoter remodelling, resulting in prolonged protein upregulation lasting weeks.
saRNAs can upregulate nuclear factors, intra-cellular proteins and secreted proteins alike, in cases where genes are both naturally expressed or epigenetically silenced.
saRNA therapeutics leverage decades of experience in the broader oligonucleotide field covering assay development, chemistry, manufacturing, formulation, clinical and regulatory.
MiNA has a strong IP position and is building a comprehensive patent portfolio. MiNA holds technology assignments and licenses from University of Texas Southwestern Medical Center, UCSF and Norwegian University of Science and Technology.